Prosecution Insights
Last updated: November 20, 2026
Application No. 18/951,832

Combination Therapies Using PRMT5 Inhibitors for the Treatment of Cancer

Non-Final OA §112§DOUBLEPATENT
Filed
Nov 19, 2024
Priority
Apr 08, 2021 — provisional 63/172,643 +2 more
Examiner
TRAN, ERIC
Art Unit
1629
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Mirati Therapeutics Inc.
OA Round
1 (Non-Final)
70%
Grant Probability
Favorable
1-2
OA Rounds
9m
Est. Remaining
89%
With Interview

Examiner Intelligence

Grants 70% — above average
70%
Career Allowance Rate
83 granted / 119 resolved
+9.7% vs TC avg
Strong +19% interview lift
Without
With
+19.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
34 currently pending
Career history
161
Total Applications
across all art units

Statute-Specific Performance

§101
2.1%
-37.9% vs TC avg
§103
30.4%
-9.6% vs TC avg
§102
16.5%
-23.5% vs TC avg
§112
33.8%
-6.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 119 resolved cases

Office Action

§112 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Currently, claims 1-17 are pending in the instant application. Priority The instant application is a CON of 17/713,455 filed on 04/05/2022, and claims priority to provisional application 63/253,029 filed on 10/06/2021, and provisional application 63/172,643 filed on 04/08/2021. Parent application 17/713,455 has issued as patent 12171765. Information Disclosure Statement The information disclosure statement (IDS) submitted on 04/30/2025 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Claim Rejections - 35 USC § 112 – Second Paragraph The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, are are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1, 6-7, 9 is indefinite for reciting “MRTX1719” without an accompanying structure, because a person of ordinary skill in the art would not reasonably be able to understand the metes and bounds of the claim. MRTX1719 appears to be a proprietary name which is not necessarily informing of the structure of the target compound. This rejection may be overcome by amending the instant claim to include the structure of MRTX1719. Claim 6 is indefinite for reciting the term “e.g.”, because a person of ordinary skill in the art would not reasonable be able to understand the metes and bounds of the claim. The indicated recitation constitutes indefinite language and it is unclear whether the limitations following the term are part of the claimed invention. Claim 7 is indefinite for reciting the term “such as”, because a person of ordinary skill in the art would not reasonable be able to understand the metes and bounds of the claim. The indicated recitation constitutes indefinite language and it is unclear whether the limitations following the term are part of the claimed invention. Claim 9 is indefinite for reciting “wherein the PRMT5 inhibitor is a methyladenosine(MTA)-cooperative PRMT5 inhibitor”, because a person of ordinary skill in the art would not reasonable be able to understand the metes and bounds of the claim. Claim 1 to which the instant claim depends upon defines the PRMT5 inhibitor as compound MRTX1719. It is unclear how the instant claim further limits the compound of MRTX1719. Claim Rejections - 35 USC § 112 - First Paragraph The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-17 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for a combination of MRTX1719 and palbociclib, does not reasonably provide enablement for a combination of MRTX1719 and any CDK4/6 inhibitor. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make use of the invention commensurate in scope with these claims. Claim 1 is drawn to a method of treating cancer by administering to a subject a combination of CDK4/6 inhibitor and MRTX1719. Under broadest reasonable interpretation the recitation of a “CDK4/6” inhibitor would encompass any compound having inhibitory action on CDK4/6 enzymes or enzymatic activity. Looking towards Applicant’s working examples for guidance, Examples 3-9 appear to demonstrate combinations of MRTX1719 and palbociclib. While palbociclib is indeed classified as a CDK4/6 inhibitor, it cannot be considered as representative of any possible CDK4/6 inhibitor which would be encompassed by the claim. Furthermore, no working examples are provided of a combination of MRTX1719 with any other CDK4/6 inhibitor. Accordingly, it would require an undue amount of experimentation for a person of ordinary skill in the art to make use of the invention as said experimentation would include the biological testing of MRTX1719 in combination with any and all CDK4/6 inhibiting compounds. None of the dependent claims ameliorate the improper scope of enablement. With regards to claim 8 which narrows the CDK4/6 inhibitor to palbociclib, abemaciclib, ribociclib, PF-06873600, and combinations thereof, the sole testing of palbociclib with MRTX1719 would not be sufficient for the recitation of abemaciclib, ribociclib, PF-06873600, and combinations thereof. The reasons being that abemaciclib and ribociclib do not appear to share analogous structure with palbociclib, and that PF-06873600 appears to have distinct function from palbociclib. Looking towards the prior art in regards to PF-06873600, Xi (Current Oncology Reports (2020) 22: 57) indicates that PF-06873600 is a selective inhibitor of CDK2/4/6 which has utility as a post CDK4/6 therapy (page 56)1 independent from palbociclib. Accordingly, palbociclib cannot be considered as representative of each of the recited species. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-17 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-18 of U.S. Patent No. 12171765 (herein the ‘765 patent). Although the claims at issue are not identical, they are not patentably distinct from each other because the claims are significantly overlapping in scope and are directed to essentially the same subject matter. Claim 1 of the instant application recites a method for treating cancer in a subject, the method comprising: administering to the subject a therapeutically effective amount of a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor and a therapeutically effective amount of a protein arginine N- methyl transferase 5 (PRMT5) inhibitor, wherein the PRMT5 inhibitor is MRTX1719 or a pharmaceutically acceptable salt thereof. Claim 1 of the ‘765 patent recites a method for treating cancer in a subject, the method comprising: administering to the subject a therapeutically effective amount of palbociclib and a therapeutically effective amount of a compound of the formula PNG media_image1.png 255 438 media_image1.png Greyscale As can be seen above, the claims of the ‘765 patent appear to fall squarely within the breadth of the instant application. The ‘765 patent is directed to combination of palbociclib and MRTX1719, while the instant application is drawn to a combination of CDK4/6 inhibitor and MRTX1719. As palbociclib is considered a CDK4/6 inhibitor, and the claims of both the instant application and ‘765 patent are drawn to methods of treating the same disease (cancer), the ‘765 patent is encompassed by the claims of the instant application. Accordingly, the claims of the instant application and the claims of the ‘765 patent cannot be considered as patentably distinct from one another. Conclusion Claims 1-17 are rejected. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ERIC TRAN whose telephone number is (571)272-7854. The examiner can normally be reached Mon-Fri 8:00-5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey S Lundgren can be reached at (571) 272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ERIC TRAN/Examiner, Art Unit 1629 /JEFFREY S LUNDGREN/Supervisory Patent Examiner, Art Unit 1629 1 “Preclinical studies indicate that ER+ breast cancer cells can adapt quickly to CDK4/6 inhibition and evade cytostasis, in part, via noncanonical cyclin D1-CDK2-mediatedS-phase entry [39]. PF-06873600, a selective CDK2/4/6 inhibitor demonstrated activity in cyclin E amplified and RB-deficient palbociclib-resistant model, is being investigated through phase 1 trial (NCT03519178).”
Read full office action

Prosecution Timeline

Nov 19, 2024
Application Filed
Nov 13, 2026
Non-Final Rejection mailed — §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12797373
COMBINATION THERAPY FOR A DOPAMINE AGONIST
10m to grant Granted Nov 17, 2026
Patent 12788760
LIQUID PHARMACEUTICAL COMPOSITION COMPRISING ENSIFENTRINE AND GLYCOPYRROLATE
4y 2m to grant Granted Nov 10, 2026
Patent 12790329
COMPOUNDS HAVING ((3-NITROPHENYL)SULFONYL)ACETAMIDE AS BCL-2 INHIBITORS
3y 2m to grant Granted Nov 10, 2026
Patent 12780800
TRIAZOLE-PYRIDINYL SUBSTITUTED AZACYCLOHEXYL ACETIC ACID COMPOUNDS AS LPA RECEPTOR ANTAGONISTS
3y 8m to grant Granted Nov 03, 2026
Patent 12780821
COMPOUNDS HAVING ((3-NITROPHENYL)SULFONYL)ACETAMIDE AS BCL-2 INHIBITORS
3y 3m to grant Granted Nov 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
70%
Grant Probability
89%
With Interview (+19.4%)
2y 9m (~9m remaining)
Median Time to Grant
Low
PTA Risk
Based on 119 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month